Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
Covington
QuintilesIMS
AstraZeneca
Daiichi Sankyo
Mallinckrodt
Teva
Colorcon

Generated: August 20, 2018

DrugPatentWatch Database Preview

Oxcarbazepine - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for oxcarbazepine and what is the scope of oxcarbazepine patent protection?

Oxcarbazepine is the generic ingredient in three branded drugs marketed by Amneal Pharms, Sun Pharm Inds Ltd, West-ward Pharms Int, Novartis, Supernus Pharms, Ani Pharms Inc, Apotex Inc, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Sun Pharm Inds, and Taro, and is included in fourteen NDAs. There are ten patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxcarbazepine has one hundred and five patent family members in thirty-eight countries.

There are nineteen drug master file entries for oxcarbazepine. Twenty-six suppliers are listed for this compound.

Pharmacology for oxcarbazepine
Synonyms for oxcarbazepine
10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #
10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; Oxacarbazepine
10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide
28721-07-5
5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine
5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-
5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-
721O075
9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
9-oxo-2-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
9-OXO-2-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3,5,7,11,13-HEXAENE-2-CARBOXAMIDE
AB0012847
AB00393017_15
AB00393017_16
AB00393017-12
AB00393017-14
AB1004555
AC-3483
AC1L1RCU
AC1Q6NA8
AKOS005516529
AM20040094
AN-6739
API0003702
BB_SC-01874
BBL010789
BC204104
BDBM34179
BG0593
BIDD:GT0078
Bio-0527
BSPBio_003457
C-15585
C07492
CAS-28721-07-5
CC-33410
CCG-39509
CHEBI:7824
CHEMBL1068
cid_34312
CPD000048684
CS-1869
CTRLABGOLIVAIY-UHFFFAOYSA-N
D00533
D0QL3P
DB00776
Desitin brand of oxcarbazepine
DR000685
DSSTox_CID_25703
DSSTox_GSID_45703
DSSTox_RID_81075
DTXSID0045703
EINECS 249-188-8
EN300-123538
Epilexter
Epliga
FT-0630543
GP 47680
GP-47680
GTPL7254
HMS1922H17
HMS2051O04
HMS2090F13
HMS2093E10
HMS2231B12
HMS3369J22
HMS3393O04
HMS3657O11
HSDB 7524
HY-B0114
I06-0072
J10384
KBio2_002155
KBio2_004723
KBio2_007291
KBio3_002677
KBioGR_001248
KBioSS_002155
KIN-493
KS-5197
LS-60365
MCULE-9100100302
MFCD00865307
MLS000084586
MLS000759520
MLS001201742
MLS001424025
MLS006011855
MolPort-001-685-316
NC00088
NCGC00065934-02
NCGC00065934-03
NCGC00065934-04
NCGC00065934-05
NCGC00065934-06
Novartis brand of oxcarbazepine
NSC-758693
NSC758693
O0363
OCBZ
Opera_ID_818
Oxacarbazepine
Oxaleptal (TN)
Oxcarbamazepine
Oxcarbazepime
Oxcarbazepin
Oxcarbazepina
Oxcarbazepina [INN-Spanish]
Oxcarbazepine (JAN/USAN/INN)
Oxcarbazepine (USAN/INN)
Oxcarbazepine [INN]
Oxcarbazepine [USAN:USP:INN:BAN]
Oxcarbazepine-13C6 solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Oxcarbazepine-d4
Oxcarbazepine, >=98% (HPLC), solid
Oxcarbazepine, analytical standard
Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard
Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard
Oxcarbazepinum
Oxcarbazepinum [INN-Latin]
oxecarb
Oxtellar (TN)
Pharmakon1600-01504243
PL039783
regid866068
s1391
SAM001246754
SBI-0206772.P001
SC-16252
SCHEMBL35129
SMR000048684
SPBio_000345
Spectrum_001675
SPECTRUM1504243
Spectrum2_000483
Spectrum3_001669
Spectrum4_000634
Spectrum5_001869
SPN-804
STK594696
Timox
Tox21_110983
Tox21_110983_1
Trileptal
Trileptal (TN)
UNII-VZI5B1W380
VZI5B1W380
W-107033
W-2542
ZB000586
ZINC4724

US Patents and Regulatory Information for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077794-002 Oct 9, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 ➤ Sign Up ➤ Sign Up
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 ➤ Sign Up ➤ Sign Up
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 ➤ Sign Up ➤ Sign Up
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for oxcarbazepine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,149 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
8,211,464 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
9,119,792 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Covington
US Army
Chubb
Fuji
Healthtrust
Federal Trade Commission
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.